£2bn pharma investment returns to UK – but will NHS patients feel the benefit?

The UK pharmaceutical industry is showing signs of an investment recovery, with £2 billion of new commitments announced over the past year as changes to NHS medicines spending and access begin to make Britain more attractive to global drug companies.

A new report from the Association of the British Pharmaceutical Industry (ABPI) says the UK has begun to reverse the disinvestment seen during 2025, when concerns about access to medicines, pricing and the commercial environment contributed to major investments being pulled or paused.

Since September 2025, pharmaceutical companies have committed £2 billion of new investment across the UK, ranging from artificial intelligence-enabled drug discovery and research through to large-scale medicines manufacturing.

Foreign investment figures also suggest an improvement. The UK attracted £167.2 million of pharmaceutical foreign direct investment during the first six months of 2026, almost twice the £88.8 million recorded during the whole of 2025.

Across the wider life sciences sector, £693 million of foreign direct investment was attracted during the first half of this year.

But the significance of the changes extends beyond pharmaceutical companies and the wider economy. Some of the policies designed to encourage companies to invest in Britain are also changing how the NHS assesses, purchases and provides new medicines to patients.

In April, the cost-effectiveness threshold used by the National Institute for Health and Care Excellence (NICE) was increased from £20,000–£30,000 to £25,000–£35,000 per quality-adjusted life year.

The threshold helps NICE determine whether the health benefits offered by a medicine represent sufficient value for it to be recommended for NHS use.

According to the ABPI, the impact was almost immediate. Nine additional medicines were approved for use in England and Wales between April and June that would not have been approved under the previous threshold.

The government has also committed to doubling UK investment in innovative medicines to at least 0.6% of GDP over the next decade.

For patients, the intention is that greater spending and a more favourable environment for pharmaceutical innovation will eventually translate into faster and broader access to new treatments.

However, the ABPI’s report suggests there is still considerable distance to travel.

The UK currently ranks fifth among eight European comparator countries for the availability of new medicines, with only 33% made fully available for their licensed use between 2021 and 2024.

The country also ranked last among five European comparators for the adoption of new medicines in 2023, 2024 and 2025.

That distinction is important. A medicine being approved does not necessarily mean patients across the NHS immediately receive it at the same rate as patients elsewhere. How quickly health services adopt new treatments can determine whether pharmaceutical innovation translates into changes in everyday patient care.

Clinical research presents another mixed picture.

Regulatory approval has become considerably faster, with 98% of UK clinical trial applications now receiving approval within 60 days, or 90 days for advanced therapy studies. However, progress slows once trials move towards actually recruiting patients.

Only 58% of industry trials opened for recruitment within 60 days of receiving approval, while just 44% recruited their first participant within 30 days of recruitment beginning.

Patient recruitment to interventional industry clinical trials also fell by 25% between 2022/23 and 2024/25.

That matters both economically and clinically. Clinical trials can give patients opportunities to access experimental treatments while generating income for the NHS and helping researchers establish whether new medicines work.

The potential economic rewards of rebuilding Britain’s pharmaceutical sector are substantial, although the figures are projections produced for the industry.

Pharmaceutical companies currently support more than 125,000 jobs across the UK. The ABPI estimates that accelerating investment and growth could create as many as another 81,300 jobs by 2035, expanding the workforce to around 200,000.

It estimates the industry’s direct contribution to the economy could consequently increase from £20.4 billion to £33.4 billion a year.

There are other signs of improvement. The median time taken by the Medicines and Healthcare products Regulatory Agency to approve a new medicine fell from 427 days in 2024 to 378 days in 2025.

Meanwhile, a new Health Data Research Service, backed by £600 million from government and Wellcome, is intended to make better use of the UK’s extensive healthcare data for research.

The ABPI nevertheless describes the recovery as fragile rather than complete.

Britain is competing against countries around the world for pharmaceutical research, manufacturing and investment, and other governments are strengthening their own offers. Ireland increased its research and development tax credit from 30% to 35% this year, while Japan introduced a 40% credit for strategic technologies including pharmaceuticals.

ABPI chief executive Dr Richard Torbett said the picture was considerably more hopeful than a year ago, but warned that the recovery was not yet secure. The organisation argues that companies making investment decisions stretching decades into the future will want evidence that government commitments will actually be delivered.

For the NHS and its patients, that delivery will ultimately matter more than the size of investment announcements.

A £2 billion return of pharmaceutical investment is potentially significant for Britain’s economy, scientific community and healthcare sector. More research, manufacturing and clinical trials could create jobs while strengthening the country’s position in developing new treatments.

But pharmaceutical competitiveness and patient benefit are not automatically the same thing.

The real measure of the UK’s pharmaceutical recovery will be whether new medicines reach patients more quickly, clinical trials become easier to access and investment in innovation ultimately translates into better treatment and health outcomes.

The money may be returning. The next question is whether patients will feel the difference.

Stay informed with the stories shaping health and social care.